The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study
Abstract
Background/objectives Diabetic subjects are at increased risk of subtle cognitive impairment since the disease early stages and of dementia later in life. In animal models, glucagon-like peptide-1 receptor agonizts (GLP1-RAs) have been shown to exert neuroprotective effects, expecially in the memory domain. We assessed whether treatment with a GLP1-RA might affect cognitive functions in type 2 diabetic subjects independently on the weight loss it might induce. Subjects/methods Forty metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes mellitus, received liraglutide (1.8 mg/d) (n = 20) or lifestyle counseling (dietary intervention and exercise training) (n = 20) until achieving a modest and comparable weight loss (-7% of initial body weight). Interventions/methods A detailed neuropsychological assessment before and after weight loss was completed in 16 patients per arm, who were administered a total of seven psychological tests, thus assessing three composite domain z-scores for attention, memory, and executive control. Results After comparable weight loss and superimposable glycemic control and insulin sensitivity, a significant increase in short term memory (mean Digit Span Z score from -0.06 to 0.80, p = 0.024) and memory composite z-score (mean memory z-score from -0.67 to 0.032, p = 0.0065) was observed in the liraglutide exposed subjects (between group p = 0.041 and p = 0.033, respectively). Conclusions Liraglutide might slow down memory f…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Human studies have demonstrated that for those with obesity, prediabetes, or early-stage T2D, liraglutide slows a decline of memory function independent of weight reduction. 103”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [103]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 1×
“Right after a frequent sampling OGTT was performed for assessment of insulin sensitivity (Matsuda index, HOMA-IR) [20, 21], and beta cell function (OGTT beta index) [22].”
MethodStandards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“In the last few years, a novel class of diabetes drugs, glucagon-like peptide-1 receptor analogs (GLP-1-RA) have been introduced for treatment of type 2 diabetes mellitus and obesity [12, 13].”
BackgroundMatsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
(1995) · Cited by 2,809
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study
Whitmer, R. A., Gunderson, E. P., Barrett-Connor, E., Quesenberry, C. P., & Yaffe, K. (2005) · BMJ · doi:10.1136/bmj.38446.466238.e0 · Cited by 1,090
Glucose Levels and Risk of Dementia
Crane, P. K., Walker, R., Hubbard, R. A., Li, G., Nathan, D. M., Zheng, H., Haneuse, S., Craft, S., Montine, T. J., Kahn, S. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215740 · Cited by 929
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Rey-Osterrieth complex figure: normative values in an Italian population sample
Caffarra, P., Vezzadini, G., Dieci, F., Zonato, F., & Venneri, A. (2002) · Neurological Sciences · doi:10.1007/s100720200003 · Cited by 722
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
“103 It is well established that mitochondria changes contribute to AD development.”
BackgroundAstrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives
Beard, E., Lengacher, S., Dias, S., Magistretti, P. J., & Finsterwald, C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.825816 · Cited by 302
Nørgaard, C. H., Friedrich, S., Hansen, C. T., Gerds, T., Ballard, C., Møller, D. V., Knudsen, L. B., Kvist, K., Zinman, B., Holm, E., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12268 · Cited by 206
Metadata
- Authors
- Vadini, F., Simeone, P. G., Boccatonda, A., Guagnano, M. T., Liani, R., Tripaldi, R., Di Castelnuovo, A., Cipollone, F., Consoli, A., & Santilli, F.
- Affiliations
- Azienda USL di Pescara (IT)
- University of Chieti-Pescara (IT)
- Corresponding author
- Santilli, Francesca
- ORCID
- Venue
- International Journal of Obesity
- Published
- 2020-01-21
- Volume
- 44
- Issue
- 6
- Pages
- 1254-1263
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W3001373148
- Cited by
- 110
- References
- 48
- Citations by year
- 2026: 8 · 2025: 31 · 2024: 15 · 2023: 18 · 2022: 23 · 2021: 7 · 2020: 8
- FWCI
- 10.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- liraglutide, GLP-1 receptor agonists, memory, cognitive function, type 2 diabetes, prediabetes, obesity, weight loss, metformin, lifestyle intervention, executive function, attention, neuroprotection
- MeSH terms
- Liraglutide, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Life Style, Longitudinal Studies, Male, Memory, Metformin, Middle Aged, Neuropsychological Tests, Obesity, Prediabetic State, Psychometrics, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. https://app.cochat.ai/papers/10.1038/s41366-020-0535-5
- The paper
- Vadini, F., Simeone, P. G., Boccatonda, A., Guagnano, M. T., Liani, R., Tripaldi, R., Di Castelnuovo, A., Cipollone, F., Consoli, A., & Santilli, F. (2020). Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. International Journal of Obesity. https://doi.org/10.1038/s41366-020-0535-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.